Related Experiment Video
Updated: Jun 20, 2026

Milk Collection Methods for Mice and Reeves' Muntjac Deer
Published on: July 19, 2014
Transfer of metyrapone and its metabolite, rac-metyrapol, into breast milk
Neil J Hotham1, Kenneth F Ilett, L Peter Hackett
1Department of Pharmacy, Women's and Children's Hospital, North Adelaide, South Australia.
Abstract:
Metyrapone, an inhibitor of corticosteroid biosynthesis, is used in the diagnosis and treatment of adrenocortical hyperfunction. The authors describe the excretion of metyrapone and its metabolite, rac-metyrapol, in milk from a lactating woman requiring metyrapone treatment (250 mg 4 times daily). At steady state, the average concentrations in milk and absolute and relative infant doses were 11 microg/L, 1.7 microg/kg/d, and 0.02%, respectively, for metyrapone, and 48.5 microg/L, 7.3 microg/kg/d, and 0.08%, respectively, for rac-metyrapol. The findings suggest that maternal metyrapone use during breastfeeding is extremely unlikely to be a significant risk for the breastfed infant.
Related Concept Videos
Drug Excretion: Miscellaneous Routes
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Drug Elimination: Non-Renal Routes
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
Pharmacokinetics in Pediatric Patients: Drug Excretion
